The medication has a half-life of approximately seven days, which allows for once-weekly dosing and contributes to stable blood levels throughout the week
Employers should keep in mind that indication-based coverage decisions (such as covering GLP-1 drugs for diabetes treatment but not for treatment of obesity or other conditions, such as addiction) can potentially raise concerns under the Americans with Disabilities Act (ADA), the ACA, HIPAAs nondiscrimination requirements, or the Mental Health Parity and Addiction Equity Act, among other laws
Our methylcobalamin guide covers alternatives
3 Extended Administration Pharmacokinetics in DIO Mice Neelakantan et al., Biochemical Pharmacology (2024) This study reported a 28-day once-daily administration protocol of 5-Amino-1MQ in diet-induced obese mice, characterizing plasma pharmacokinetics, tissue distribution, and effects on body composition, fatty liver pathology, and circulating biomarkers
I do recommend this company, though